Pulsed Field Ablation Cleared for Atrial Fibrillation: Implications for Cardiothoracic Practice

Pulsed field ablation is now FDA-cleared for atrial fibrillation, giving cardiothoracic teams a non-thermal alternative to radiofrequency and cryoablation. The mechanism delivers tissue-selective lesions that largely spare the esophagus, phrenic nerve, and pulmonary veins.

May 19, 2026 · 3 min read

The Story at a Glance:

Pulsed field ablation has received expanded FDA clearance for atrial fibrillation, with multiple catheter systems now on the U.S. market
The non-thermal mechanism uses high-voltage electrical pulses to selectively damage cardiac myocytes via irreversible electroporation
Pivotal trials show efficacy comparable to thermal ablation with sharply lower rates of atrioesophageal and phrenic nerve injury
Procedural times are shorter, with most published cases isolating all pulmonary veins within 60 to 90 minutes

What Happened

Pulsed field ablation has secured an expanded foothold in the U.S. atrial fibrillation market, with the FDA approving multiple catheter platforms for drug-refractory paroxysmal and, increasingly, persistent disease.

Cleared systems include Boston Scientific’s Farapulse (Farawave pentaspline catheter), Medtronic’s PulseSelect (circular catheter), and Johnson & Johnson’s Varipulse. Indications cover patients who have failed at least one antiarrhythmic drug, with the most recent label updates broadening eligibility into persistent atrial fibrillation beyond the original paroxysmal cohort.

Why Pulsed Field Ablation Matters

For cardiothoracic surgeons and electrophysiology teams managing atrial fibrillation, pulsed field ablation reshapes the safety calculus. Thermal ablation — radiofrequency (RFA) and cryoballoon — injures tissue indiscriminately, putting the esophagus, phrenic nerve, and pulmonary veins themselves at risk of fistula, palsy, or stenosis.

The pulsed field ablation mechanism is fundamentally different. Short, high-voltage electrical pulses (microsecond duration) create irreversible electroporation in cell membranes, opening nanoscale pores that trigger apoptosis. Cardiac myocytes have a lower electroporation threshold than esophageal, neural, or vascular tissue, so adjacent structures are largely spared at therapeutic energy levels.

Operationally, this changes the calculus for left atrial procedures. Esophageal temperature probes, phrenic nerve pacing, and prolonged post-procedure surveillance for atrioesophageal fistula become less central to the workflow.

Key Numbers

The ADVENT trial, published in NEJM in 2023, randomized 607 patients comparing Farapulse PFA to thermal ablation (RFA or cryoballoon) in paroxysmal atrial fibrillation. Headline results:

Efficacy at 12 months: 73.3% freedom from atrial arrhythmia (PFA) vs 71.3% (thermal) — non-inferiority met
Serious adverse events: 2.1% (PFA) vs 1.5% (thermal) — also non-inferior
Mean procedure time: 105 minutes (PFA) vs 124 minutes (thermal)
Atrioesophageal fistulas: zero in the PFA arm; zero pulmonary vein stenosis
MANIFEST-PF registry (n > 1,500): near-zero phrenic nerve injury, no atrioesophageal fistulas reported in post-approval real-world use

What Experts Are Saying

“PFA achieves freedom from afib comparable to thermal ablation with a different safety profile.” — Vivek Reddy, MD, Mount Sinai Health System, on the ADVENT trial findings

Independent commentators have welcomed the safety advantages while urging caution. A 2024 Heart Rhythm Society expert consensus called for systematic post-market surveillance, citing rare but documented coronary vasospasm during ablation near coronary arteries — particularly the mitral isthmus — and transient hemolysis in some early post-approval case series.

What’s Next for Pulsed Field Ablation

Indications continue to expand. Persistent atrial fibrillation labeling is now in place across most cleared systems, with active trials evaluating PFA in atrial flutter and ventricular tachycardia. Medtronic’s Affera Sphere-9 catheter combines pulsed field and radiofrequency energy in a single device, simplifying ablation in heterogeneous substrates.

Procedurally, teams adopting pulsed field ablation should plan for general anesthesia (skeletal muscle contraction is universal during pulse delivery), bilateral femoral venous access with transseptal puncture, and 8 to 16 applications per pulmonary vein in 2 to 3 second bursts. Most operators reach consistent isolation within 10 to 15 cases.

Bottom Line

Identify symptomatic, drug-refractory atrial fibrillation patients who may benefit from pulsed field ablation referral
Counsel patients on the trade-offs: efficacy comparable to thermal ablation, lower atrioesophageal risk, but limited 5-year durability data
Plan credentialing and team training pathways early — workflow differs from RFA despite anatomic similarities
Monitor post-procedure for rare complications including coronary vasospasm and transient hemolysis, especially with mitral isthmus ablation

Sources

Reddy VY, Gerstenfeld EP, Natale A, et al. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. New England Journal of Medicine, November 2023. ADVENT Trial — NEJM 2023
Verma A, Haines DE, Boersma LV, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation, May 2023. PULSED AF Pivotal Trial — Circulation 2023
Ekanem E, Reddy VY, Schmidt B, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace, 2022. MANIFEST-PF Registry — Europace 2022
U.S. Food and Drug Administration. Premarket Approval — Farapulse Pulsed Field Ablation System. FDA.gov. FDA Premarket Approval Database